【レポートの概要（一部）】
1. Report Overview
1.1 Global Asthma and COPD Therapies Market Overview
1.2 Global Asthma and COPD Therapies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Asthma and COPD Therapies
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 Overview of Respiratory Diseases
2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive
2.3 What is Asthma?
2.3.1 Trends in Asthma Prevalence
2.3.2 Pathophysiology of Asthma
2.3.3 Symptoms of Asthma
2.3.4 Causes and Triggers for Asthma
2.3.5 Treatment of Asthma
2.3.6 Guidelines for Asthma Treatment
2.3.7 Drug Treatments for Asthma
2.3.8 Drug Delivery Methods in Asthma
2.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
2.4.1 Trends in COPD Prevalence
2.4.2 Pathophysiology of COPD
2.4.3 Signs and Symptoms of COPD
2.4.4 Treatment of COPD
2.4.5 Drug Treatments for COPD
2.4.6 Guidelines for COPD Treatment
2.5 Major Drug Classes in the Treatment of Asthma and COPD
2.5.1 Bronchodilators
2.5.1.1 Beta2-Agonists
2.5.1.2 Anticholinergics
2.5.2 Anti-Inflammatory Drugs
2.5.2.1 Corticosteroids
2.5.2.2 Leukotriene Receptor Antagonists
2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
2.5.3 Combination Drugs
2.5.4 Drugs for Allergic Rhinitis
2.6 Phases of Clinical Trials
2.7 Scope of this Report
2.8 Currency Exchange Rates in This Report
3. Asthma and COPD Therapies: World Market 2014-2024
3.1 The World Respiratory Drugs Market by Therapeutic Area
3.2 The World Asthma and COPD Therapies Market in 2013
3.2.1 Leading Asthma and COPD Therapies
3.2.2 Leading Companies in the Asthma and COPD Therapies Market
3.3 World Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2014-2024
3.3.1 World Asthma Therapies Market: Sales Forecast 2014-2024
3.3.2 World COPD Therapies Market: Sales Forecast 2014-2024
3.4 World Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2014-2024
3.5 Combination Drugs Lead the Asthma and COPD Therapies Market
3.6 How Will Segmental Market Shares Change to 2024?
3.6.1 World Asthma and COPD Therapies Market: Drivers and Restraints 2014-2024
3.7 Asthma and COPD Therapies: Trends and Developments
3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?
4. Leading National Markets 2014-2024
4.1 Regional Breakdown of the World Asthma and COPD Therapies Market
4.2 World Asthma and COPD Therapies Market: Regional Forecast 2014-2024
4.2.1 How Will Regional Market Shares Change to 2024?
4.3 National Breakdown of the World Asthma and COPD Therapies Market
4.4 World Asthma and COPD Therapies Market: National Markets Forecast 2014-2024
4.4.1 How Will National Market Shares Change to 2024?
4.5 The US Asthma and COPD Therapies Market 2014-2024
4.5.1 US Asthma and COPD Therapies Market Forecast 2014-2024
4.5.2 US Asthma and COPD Therapies Market: Trends and Developments
4.5.2.1 Increasing COPD Prevalence in the US
4.5.2.2 FDA Issues Draft Guidance on Generic Inhaler Bioequivalence
4.5.2.3 Pharmacy Benefit Managers Alter Formulary Status of Advair
4.6 Japanese Asthma and COPD Therapies Market 2014-2024
4.6.1 Japanese Asthma and COPD Therapies Market Forecast 2014-2024
4.6.2 Japanese Asthma and COPD Therapies Market: Trends and Developments
4.6.2.1 Generic Penetration to Reach 60% by 2018?
4.6.2.2 Japanese Pharmaceutical Industry Regulatory Reform
4.7 EU5 Asthma and COPD Therapies Market 2014-2024
4.7.1 German Asthma and COPD Therapies Market Forecast 2014-2024
4.7.2 French Asthma and COPD Therapies Market Forecast 2014-2024
4.7.3 UK Asthma and COPD Therapies Market Forecast 2014-2024
4.7.4 Italian Asthma and COPD Therapies Market Forecast 2014-2024
4.7.5 Spanish Asthma and COPD Therapies Market Forecast 2014-2024
4.7.6 EU5 Asthma and COPD Therapies Market: Trends and Developments
4.7.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
4.7.6.2 France: Social Security Finance Bill 2014
4.7.6.3 UK: Improving Asthma and COPD Patient Outcomes
4.7.6.4 Italy: Austerity Measures Limiting Growth
4.7.6.5 Spain: The Start of Recovery in the Spanish Economy
4.8 BRIC Asthma and COPD Therapies Market 2014-2024
4.8.1 Chinese Asthma and COPD Therapies Market Forecast 2014-2024
4.8.2 Chinese Asthma and COPD Therapies Market: Trends and Developments
4.8.2.1 China’s Industrial Future and Asthma/COPD
4.8.2.2 Expansion of Healthcare Coverage and Reimbursement
4.8.2.3 Price Controls and the Anhui Model
4.8.3 Brazilian Asthma and COPD Therapies Market Forecast 2014-2024
4.8.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments
4.8.4.1 Increasing Access to Medicines
4.8.5 Indian Asthma and COPD Therapies Market Forecast 2014-2024
4.8.6 Indian Asthma and COPD Therapies Market: Trends and Developments
4.8.6.1 Drug Prices Control Order 2013
4.8.6.2 Expansion of Healthcare Provision
4.8.7 Russian Asthma and COPD Therapies Market Forecast 2014-2024
4.8.8 Russian Asthma and COPD Therapies Market: Trends and Developments
4.8.8.1 No Embargo on Foreign Drug Imports
4.8.8.2 Pharma2020 and the Russian Pharmaceutical Industry
4.9 Mexican Asthma and COPD Therapies Market 2014-2024
4.9.1 Mexican Asthma and COPD Therapies Market Forecast 2014-2024
4.9.2 Mexican Asthma and COPD Therapies Market: Trends and Developments
4.9.2.1 Seguro Popular: Mexican Healthcare Reform
4.9.2.2 COFEPRIS: Regulatory Changes and Improvements
4.9.2.3 Mexico’s Agreement for Innovation
5. Bronchodilator Monotherapy Market 2014-2024
5.1 Introduction to Bronchodilator Monotherapy
5.2 The Bronchodilator Monotherapy Market in 2013
5.2.1 Leading Bronchodilators in 2013
5.3 Bronchodilator Monotherapy: Market Forecast 2014-2024
5.4 How Will Market Shares by Drug Class Change to 2024?
5.5 The Short-Acting Beta2-Agonist (SABA) Market 2014-2024
5.5.1 Leading SABAs in 2013
5.5.2 SABAs: Market Forecast 2014-2024
5.5.3 Market Share of Leading SABAs to 2024
5.5.4 Ventolin (salbutamol, GSK)
5.5.4.1 Ventolin: Sales Forecast 2014-2024
5.5.5 ProAir (salbutamol, Teva)
5.5.5.1 ProAir: Sales Forecast 2014-2024
5.5.6 Proventil (salbutamol, Merck)
5.5.6.1 Proventil: Sales Forecast 2014-2024
5.5.7 Xopenex (levosalbutamol, Dainippon Sumitomo)
5.5.7.1 Xopenex: Sales Forecast 2014-2024
5.6 The Long-Acting Beta2-Agonist (LABA) Market 2014-2024
5.6.1 Leading LABAs in 2013
5.6.2 LABAs: Market Forecast 2014-2024
5.6.3 Market Share of Leading LABAs to 2024
5.6.4 Foradil (formoterol, Merck/Novartis)
5.6.4.1 Foradil: Sales Forecast 2014-2024
5.6.5 Serevent (salmeterol, GSK)
5.6.5.1 Serevent: Sales Forecast 2014-2024
5.6.6 Arcapta/Onbrez (indacaterol, Novartis)
5.6.6.1 Arcapta/Onbrez: Sales Forecast 2014-2024
5.6.7 Brovana (arfomoterol, Dainippon Sumitomo)
5.6.7.1 Brovana: Sales Forecast 2014-2024
5.6.8 Striverdi (olodaterol, Boehringer Ingelheim)
5.6.8.1 Striverdi: Sales Forecast 2014-2024
5.7 The Anticholinergics Market 2014-2024
5.7.1 Leading Anticholinergics in 2013
5.7.2 Anticholinergics: Market Forecast 2014-2024
5.7.3 Market Share of Leading Anticholinergics to 2024
5.7.4 Spiriva (tiotropium, Boehringer Ingelheim)
5.7.4.1 Spiriva: Sales Forecast 2014-2024
5.7.5 Spiriva: Recent Developments
5.7.5.1 Safety Concerns and the UPLIFT Trial
5.7.5.2 Results of the POET Study
5.7.5.3 Competition from Combination Products
5.7.6 Atrovent (ipratropium, Boehringer Ingelheim)
5.7.6.1 Atrovent: Sales Forecast 2014-2024
5.7.7 Eklira/Tudorza/Bretaris (aclidinium, AstraZeneca/Forest/Menarini)
5.7.7.1 Eklira/Tudorza/Bretaris: Sales Forecast 2014-2024
6. Anti-Inflammatory Drugs Market 2014-2024
6.1 Introduction to Anti-Inflammatory Drugs
6.2 The Anti-Inflammatory Drugs Market in 2013
6.2.1 Leading Anti-Inflammatory Drugs in 2013
6.3 Anti-Inflammatory Drugs: Market Forecast 2014-2024
6.4 How Will Market Shares by Drug Class Change to 2024?
6.5 The Corticosteroids Market 2014-2024
6.5.1 Leading Corticosteroids in 2013
6.5.2 Corticosteroids: Market Forecast 2014-2024
6.5.3 Market Share of Leading Corticosteroids to 2024
6.5.4 Flixotide/Flovent (fluticasone propionate, GSK)
6.5.4.1 Flixotide/Flovent: Sales Forecast 2014-2024
6.5.5 Pulmicort (budesonide, AstraZeneca)
6.5.5.1 Pulmicort: Sales Forecast 2014-2024
6.5.6 QVAR (beclometasone, Teva)
6.5.6.1 QVAR: Sales Forecast 2014-2024
6.5.7 Asmanex (mometasone, Merck)
6.5.7.1 Asmanex: Sales Forecast 2014-2024
6.6 The Anti-Leukotrienes Market 2014-2024
6.6.1 Leading Anti-Leukotrienes in 2013
6.6.2 Anti-Leukotrienes: Market Forecast 2014-2024
6.6.2.1 Market Share of Leading Anti-Leukotrienes to 2024
6.6.3 Singulair (montelukast, Merck)
6.6.3.1 Singulair: Sales Forecast 2014-2024
6.7 The Monoclonal Antibodies Market 2014-2024
6.7.1 Monoclonal Antibodies: Market Forecast 2014-2024
6.7.1.1 Market Share of Leading Monoclonal Antibodies to 2024
6.7.2 Xolair (omalizumab, Novartis/Roche)
6.7.2.1 Xolair: Sales Forecast 2014-2024
6.7.3 Cinquil (reslizumab, Teva)
6.7.3.1 Cinquil: Sales Forecast 2014-2024
6.7.4 Mepolizumab (Bosatria, GSK)
6.7.4.1 Mepolizumab: Sales Forecast 2014-2024
6.7.5 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
6.7.5.1 Benralizumab: Sales Forecast 2014-2024
6.7.6 Lebrikizumab (RG3637, Roche)
6.7.6.1 Lebrikizumab: Sales Forecast 2014-2024
6.7.7 Dupilumab (REGN668, Regeneron/Sanofi)
6.7.7.1 Dupilumab: Sales Forecast 2014-2024
7. Combination Drugs Market 2014-2024
7.1 Introduction to Combination Drugs
7.1.1 Leading Combination Drugs in 2013
7.2 Combination Drugs: Market Forecast 2014-2024
7.3 How Will Market Shares by Drug Change to 2024?
7.3.1 Advair/Seretide (fluticasone/salmeterol, GSK)
7.3.1.1 Advair/Seretide: Sales Forecast 2014-2024
7.3.2 Symbicort (budesonide/formoterol, AstraZeneca)
7.3.2.1 Symbicort: Sales Forecast 2014-2024
7.3.2.2 Symbicort: The SMART Concept
7.3.3 Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
7.3.3.1 Combivent: Sales Forecast 2014-2024
7.3.4 Dulera (formoterol/mometasone, Merck)
7.3.4.1 Dulera: Sales Forecast 2014-2024
7.4 Recently Launched Combination Drugs
8. Leading Companies in the Asthma and COPD Therapies Market
8.1 Asthma and COPD Therapies: Increasing Competition
8.1.1 Leading Companies in Asthma and COPD in 2013
8.1.2 Leading Companies: Market Forecast 2014-2024
8.1.3 How Will Leading Companies’ Market Shares Change to 2024?
8.2 AstraZeneca
8.2.1 AstraZeneca: Asthma and COPD Therapies
8.2.2 AstraZeneca: Sales Forecast 2014-2024
8.2.3 AstraZeneca: Products in Development
8.2.4 AstraZeneca: Recent Developments
8.2.4.1 AstraZeneca Acquires Almirall’s Respiratory Portfolio
8.2.4.2 Acquisition of Pearl Therapeutics Expanded AstraZeneca’s Combination Drug Pipeline
8.2.4.3 AstraZeneca Rejects Pfizer Takeover Bid
8.3 Boehringer Ingelheim
8.3.1 Boehringer Ingelheim: Asthma and COPD Therapies
8.3.2 Boehringer Ingelheim: Sales Forecast 2014-2024
8.3.3 Boehringer Ingelheim: Products in Development
8.3.4 Boehringer Ingelheim: Recent Developments
8.3.4.1 Expansion of Respimat Manufacturing Capacity
8.3.4.2 Respimat Safety Concerns and the TIOSPIR Study
8.3.4.3 Ben Venue Laboratories Shut Down
8.4 GSK
8.4.1 GSK: Asthma and COPD Therapies
8.4.2 GSK: Sales Forecast 2014-2024
8.4.3 GSK: Products in Development
8.4.4 GSK: Recent Developments
8.4.4.1 Breo/Relvar and Anoro: Recently Launched Combination Drugs
8.4.4.2 Arnuity Ellipta Approved in the US
8.4.4.3 GSK Divests OTC Products
8.4.4.4 GSK Asset Swap with Novartis to Restructure Consumer Health
8.4.4.5 GSK Presents Data on Eosinophil Levels and COPD
8.5 Merck & Co. (Merck)
8.5.1 Merck: Asthma and COPD Therapies
8.5.2 Merck: Sales Forecast 2014-2024
8.5.3 Merck: Products in Development
8.5.4 Merck: Recent Developments
8.5.4.1 Bayer Acquires Merck’s Consumer Health Business
8.5.4.2 FDA Rejects Singulair OTC Switch
8.5.4.3 Takeda Ended Co-Promotion of Daxas with Merck
8.6 Novartis
8.6.1 Novartis: Asthma and COPD Therapies
8.6.2 Novartis: Sales Forecast 2014-2024
8.6.3 Novartis: Products in Development
8.6.4 Novartis: Recent Developments
8.6.4.1 Novartis Restructures Following Strategic Review
8.6.4.2 Novartis Presents Data on Ultibro and Seebri
8.6.4.3 Pfizer Promotes Two Novartis COPD drugs in the UK
8.7 Roche
8.7.1 Roche: Asthma and COPD Therapies
8.7.2 Roche: Sales Forecast 2014-2024
8.7.3 Roche: Products in Development
8.8 Teva
8.8.1 Teva: Asthma and COPD Therapies
8.8.2 Teva: Sales Forecast 2014-2024
8.8.3 Teva: Products in Development
8.8.4 Teva: Recent Developments
8.8.4.1 Launch of DuoResp Spiromax
【レポート販売概要】
■ タイトル：世界の喘息及びCOPD（慢性閉塞性肺疾患）治療薬市場■ 英文：Asthma and COPD Therapies Market Forecast 2014-2024 : Opportunities for Leading Companies
■ 発行日：2014年10月
■ 調査会社：visiongain
■ 商品コード：VGAIN4120203
■ 調査対象地域：グローバル
- 結腸直腸癌治療薬の世界市場2019-2023Technavio Announces the Publication of its Research Report – Global Colorectal Cancer Therapeutics Market 2019-2023 Technavio recognizes the following companies as the key players in the global colorectal cancer therapeutics market: Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sanofi. Commenting on the report, an analyst from Technavio’s team sa …
- プレストレスト・コンクリート（PC）ワイヤ＆ストランドの世界市場ABSTRACTAbout Prestressed Concrete (PC) Wire and Strand The artificial compression stress applied to neutralize tensile stress deployed by exterior force is known as prestress. The structures constructed with prestress is called PC. The wire or strand used on PC structure is known as PC wire or strand. When force is applied to the concrete, prestressing is introduced to counter the stresses result …
- C4ISR（指揮・統制・通信・コンピューター・情報・監視・偵察）の世界市場：競争環境、戦略的インサイトSummary This report shows the leading C4ISR market segments in various regions across the world. Details of top companies active across the global C4ISR market are provided, together with market size and forecast 2014-2024 for the main players across those areas. Key Findings The report provides a detailed analysis of the competitive landscape of the C4ISR market. It provides an overview of key C4 …
- 神経血管インターベンション（Neurovascular Intervention）：企業動向MediPoint: Neurovascular Interventions - Current and Future Players Summary The global neurovascular interventions market is a vast, double-digit market that consists of innovative and emerging technologies. Rapid advances in the field of neurovascular interventions and development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. The neurovascular i …
- 世界の鉱業分析：Analyzing the Global Mining IndustryThe financial crisis of 2008 and 2009 had a major impact on the global mining industry. However, the year 2010 saw the industry recover strongly and this growth rate continued well into 2011 and the first half of 2012 as well. The global mining industry has been seeing a steady rise in mergers and acquisitions amongst the major players with the recent Xstrata and Glencore International deal making …
- Antidepressants (片頭痛/Migraine)：医薬品市場予測及び分析（～2023）Antidepressants (Migraine) - Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature pr …
- 学習管理システム（LMS）の世界市場予測（～2023年）Growth in LMS market is a major growth driver for the global LMS market The global LMS market size is expected to grow from USD 9.2 billion in 2018 to USD 22.4 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 19.6% during the forecast period during the forecast period. The major growth drivers for the market are increasing the adoption of digital learning, growing inclination towards, B …
- 哺乳瓶消毒器の世界市場2015-2019About baby bottles sterilizers The baby care products market is a sensitive market due to the emotional value attached to such products, including baby bottle sterilizers. Parents are always concerned about getting the best and safest products for their children. Thus, marketing strategies involve emotional appeal rather than logical and point-based appeals. Developing countries have witnessed rap …
- モバイルコマースベンダー分析2012（Mobile Commerce Vendor Analysis 2012）There are a wide variety of factors that define the success of a mobile technology including instant connectivity, convenience, and personalization. Successful mobile applications are typically perceived by their users as being accessible anytime and anywhere, highly adaptable to the user's needs, and not revealing any private information about the user. However, many potential consumers of mobile …
- 世界の透明セラミックス市場2015The Global Transparent Ceramics Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Transparent Ceramics industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Transparent Ceramics market analysis is provided for the international markets including develop …
- 2014年イタリアの分子血液型・分類検査および感染症NAT（核酸増幅検査）市場Complete report $6,100. DataPack (test volumes, sales forecasts, supplier shares) $3,950. This comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the Italian molecular blood banking market during the next five years, and assist industry executives in developing effective business, new product development an …
- 2014年戦略提言：日本の血液及びフローサイトメトリー市場Complete report $8,800. DataPack (test volumes, sales forecasts, supplier shares) $5,700.SummaryThis comprehensive report contains 250 pages, 32 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in Japanese hematology and flow cytometry markets during the next five years. The report explores business an …
- 世界のセラミックス複合材料（CMC）市場About CMC Ceramic matrix composites (CMCs) are manufactured by strengthening a ceramic matrix with a refractory fiber. The ceramic matrix can be of various types including silicon carbide and alumina matrices, among others. The reinforcements can also be made in different forms, including continuous or short fibers and particles. Because of their superior material properties such as heat and wear …
- ヘッドマウントディスプレイ（HMD/スマートグラス）の世界市場About Head Mounted Displays HMD (head mounted displays) comprise small displays with lenses and semi-transparent mirrors embedded in them, which makes them look like a pair of eyeglasses. They are also sometimes referred to as “smart glasses.” A head-mounted display consists of an image source, collimating optics, and a mechanism to mount the device on the head. The device is wearable, and project …
- ギア（歯車）製造の世界市場：ウォームギア、ベベルギア、スパーギアAbout Gear Manufacturing A gear is a rotating machine that enables the transmission of torque through meshing of cut teeth or cogs with another toothed part or rack. The ttransmission occurs by synchronous working of two or more gears using mechanical force to achieve the desired output and thus act as a simple machine. Gears are transmission devices that require human effort for operation, and ar …
